Jose Luis
Alonso Romero
Asociado Ciencias de la Salud
Hospital Clínico Universitario Lozano Blesa
Zaragoza, EspañaPublications en collaboration avec des chercheurs de Hospital Clínico Universitario Lozano Blesa (3)
2022
-
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study
European Journal of Cancer, Vol. 168, pp. 12-24
-
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study
BMC Cancer, Vol. 22, Núm. 1